|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||49.95 - 50.10|
|52-week range||42.60 - 69.40|
|Beta (5Y monthly)||1.06|
|PE ratio (TTM)||0.38|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Readers hoping to buy Cosmo Pharmaceuticals N.V. ( VTX:COPN ) for its dividend will need to make their move shortly, as...
With its stock down 17% over the past three months, it is easy to disregard Cosmo Pharmaceuticals (VTX:COPN). However...
Generally speaking long term investing is the way to go. But along the way some stocks are going to perform badly...
With a price-to-earnings (or "P/E") ratio of 53.2x Cosmo Pharmaceuticals N.V. ( VTX:COPN ) may be sending very bearish...
Medtronic's (MDT) GI Genius intelligent endoscopy module is the first FDA-cleared, AI-assisted colonoscopy tool to help physicians detect polyps that can lead to colorectal cancer.
If you want to know who really controls Cosmo Pharmaceuticals N.V. ( VTX:COPN ), then you'll have to look at the makeup...
Most readers would already be aware that Cosmo Pharmaceuticals' (VTX:COPN) stock increased significantly by 20% over...
Cosmo Pharmaceuticals N.V. ( VTX:COPN ) shareholders should be happy to see the share price up 20% in the last month...